Fate Therapeutics Welcomes New Employee with Generous Stock Options and RSUs
Fate Therapeutics has welcomed a new non-executive employee, granting them stock options and restricted stock units (RSUs) as part of their compensation package. The details of the grants were recently made public in the news.
The new employee was granted non-qualified stock options to purchase 60,000 shares of Fate Therapeutics' common stock at $1.25 per share. These options will vest over four years, with a quarter vesting after the first year and the remaining three-quarters vesting monthly over the next three years, contingent upon continuous employment. This grant was made under the company's Amended and Restated Inducement Equity Plan and approved by the Compensation Committee of the Company's Board of Directors.
In addition to the stock options, the new employee received restricted stock units (RSUs) representing 45,800 shares of common stock. These RSUs will vest 25% annually over four years, also subject to continuous employment. The recipient's identity has not been disclosed in the news, although the company reported new stock awards for employees on October 2, 2025.
Fate Therapeutics has shown commitment to its new employee, offering a comprehensive compensation package that includes stock options and RSUs. The vesting schedules for both grants ensure long-term engagement and performance alignment with the company's goals.
Read also:
- TikTok's deal negotiations continue following a conversation between Xi and Trump
- Trump announces agreement with Chinese authorities on TikTok deal
- Quantum Computing Market in the Automotive Sector Forecast to Expand to $6,462.13 Million by 2034
- Texas finalizes 1.8 billion dollars for the construction of solar, battery, and gas-fueled mini-grids
